Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
47.02 USD | -5.66% | -12.14% | -36.44% |
May. 24 | Sector Update: Health Care Stocks Advance Pre-Bell Friday | MT |
May. 24 | Exact Sciences to Present New Data at Oncology Annual Meeting Confirming Prognostic Value of Breast Cancer Test | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- Low profitability weakens the company.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's enterprise value to sales, at 3.81 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-33.06% | 9.2B | A- | ||
-4.14% | 3.12B | C | ||
+23.00% | 2.8B | D+ | ||
-17.75% | 2.07B | - | B- | |
-25.05% | 1.59B | C+ | ||
+66.11% | 1.44B | B- | ||
+31.25% | 830M | C- | ||
-6.55% | 724M | C+ | ||
-29.49% | 507M | C- | ||
-7.36% | 275M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EXAS Stock
- Ratings Exact Sciences Corporation